Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
With
Astellas Pharma US, Inc.
The purpose of this study is to assess the efficacy and safety of FK778 compared with standard care in renal transplant recipients with newly diagnosed and untreated BK nephropathy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Renal transplant recipient with newly diagnosed BK nephropathy.
You may not be if
Previous treatment for BK nephropathy
Organ transplant other than kidney
Uncontrolled concomitant infection other than BK nephropathy
